| Guo, Hong |
NCT05205603: Efficacy of Mesalazine Combined With Biologics in the Treatment of Moderate to Severe Ulcerative Colitis |
|
|
| Recruiting | 4 | 438 | RoW | Infliximab, Vedolizumab, Mesalazine | Sixth Affiliated Hospital, Sun Yat-sen University | Ulcerative Colitis, Efficacy, Self, Biologics, Mesalazine | 01/24 | 01/25 | | |
NCT06609447: The Efficacy and Safety of Combining Probiotic VSL#3 With Vedolizumab for the Treatment of Moderate Ulcerative Colitis |
|
|
| Recruiting | 4 | 100 | RoW | VSL#3, Placebo, Placebo (for VSL#3), Vedolizumab, Vedolizumab 300 mg Injection | Second Affiliated Hospital, School of Medicine, Zhejiang University | Ulcerative Colitis | 12/27 | 12/27 | | |
| Completed | 3 | 1281 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828, Placebo | Eli Lilly and Company | Ulcerative Colitis | 01/21 | 05/24 | | |
|
|
|
|
| Active, not recruiting | 3 | 1177 | Europe, Canada, Japan, US, RoW | Mirikizumab SC, LY3074828, Mirikizumab IV, Placebo SC | Eli Lilly and Company | Ulcerative Colitis | 11/21 | 12/24 | | |
|
|
NCT06512584: Efficacy and Safety of PJ009 in Patients with Short Bowel Syndrome Requiring Parenteral Nutrition |
|
|
| Recruiting | 3 | 72 | RoW | PJ009, Glucagon-Like Peptide 2 (GLP-2) analogue, PJ009 Placebo, GLP-2 analogue Placebo | Chongqing Peg-Bio Biopharm Co., Ltd. | Short Bowel Syndrome | 03/26 | 04/26 | | |
NCT05181137 / 2021-001940-86: A Phase 3 Study to Investigate the Efficacy and Safety of SHR0302 With Moderately to Severely Active Ulcerative Colitis |
|
|
| Recruiting | 3 | 368 | Europe, US, RoW | SHR0302, Placebo | Reistone Biopharma Company Limited, Reistone Biopharma Company Limited | Ulcerative Colitis | 10/24 | 03/25 | | |
| Recruiting | 3 | 778 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Crohn's Disease | 11/24 | 12/26 | | |
NCT06233461: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease |
|
|
| Recruiting | 2 | 268 | Europe, Canada, Japan, US, RoW | TAK-279, Zasocitinib, Placebo | Takeda | Crohn's Disease | 09/26 | 07/27 | | |
NCT05486104: Phase II Study of Hemay005 in Patients With Active Ulcerative Colitis |
|
|
| Recruiting | 2 | 108 | RoW | Hemay005 tablets, Hemay005 45 mg BID group, Hemay005 placebo tablets, Hemay005 placebo BID group | Ganzhou Hemay Pharmaceutical Co., Ltd | Moderate to Severe Ulcerative Colitis | 06/24 | 09/24 | | |
NCT04135027: Study of Factors and Mechanisms Influencing the Effects of Treatments in Crohn's Disease |
|
|
| Recruiting | N/A | 500 | RoW | no interventions | Second Affiliated Hospital, School of Medicine, Zhejiang University | Crohn Disease | 12/22 | 12/22 | | |
NCT04872491: A Study of Vedolizumab in Adults in Real-World Practice |
|
|
| Completed | N/A | 500 | RoW | | Takeda | Colitis, Ulcerative, Crohn Disease | 07/24 | 07/24 | | |
NCT05387031: Efficacy of Ustekinumab Therapy in Patients With Symptomatic Stricturing Crohn's Disease |
|
|
| Recruiting | N/A | 239 | RoW | Ustekinumab, Stelara | Second Affiliated Hospital, School of Medicine, Zhejiang University, Sixth Affiliated Hospital, Sun Yat-sen University, Second Affiliated Hospital of Soochow University, Chongqing Renji Hospital, University of Chinese Academy of Sciences, The First Affiliated Hospital of Zhejiang Chinese Medical University, Seventh Medical Center of PLA Army General Hospital, First People's Hospital of Hangzhou, Yangzhou University, Xian-Janssen Pharmaceutical Ltd. | Crohn Disease, Stricture; Bowel, Intestinal Stricture | 08/26 | 08/27 | | |
